Is this email not displaying correctly? View it in your browser.
Customer Quarterly Newsletter | July 2015

Therapist Focus

Karen Evans photo

Karen Evans

Registered Nurse. Lymphoedema Therapist (ALA National Practitioner Register). Remedial Massage Therapist. Adult Education & Training. Women's Health. Sexual & Reproductive Health. Palliative Care.

How long have you been using the LTU-904:

Most inspiring or intriguing laser story:
44 yr old woman with history of lymphoedema of the right leg following surgery for melanoma 5yrs previous. Contracture from scarring in the popliteal fossa with subsequent loss of range of movement. Use of laser on the popliteal fossa demonstrated immediate increase in ROM of 25% , 2nd visit increase 50% and an improvement of 75% at third visit which has been maintained with laser treatment monthly for 3mths and bimonthly 6mths. The patient was able to subsequently return to work which she had not been able to do.

What do you use the laser for:
Lymphoedema - fibrosis and radiation fibrosis, scar management, terminus clearance, trigger point.

Remedial - trigger point, scar management, reduce inflammation.


Practical workshops specifically designed for therapists using the LTU-904 low level laser are being held around Australia. You will learn comprehensive techniques that can be used to effectively treat your clients.

Treatments covered will include Lymphoedema and a variety of Muscular-Skeletal Pain issues. Other conditions by request.

Register your interest with RianCorp to be informed of the next workshop in your area.

Important note

With the Australian Government currently providing small businesses with an immediate deduction for all individual assets costing less than $20,000, now is the time to purchase a new (or additional) LTU-904 laser for your clinic. For more information regarding the Accelerated Depreciation tax break: click here 

New Research

Fibrous capsular contracture is a common complication after breast augmentation and breast reconstruction. The incidence of clinically significant capsular contracture is between 2% and 51% in nonirradiated patients and as high as 100% in patients receiving radiation.

Current treatment includes both nonsurgical options and surgical options (for the more severe cases). Regardless of the method of treatment results can vary significantly and remain unpredictable, with recurrence rates reported to be from 10% to 46%.

Recent studies with the LTU-904 laser have shown treatment can improve capsular contracture and, in most cases, even avoid surgical intervention in Grades III to IV contracture. Further research is currently underway in both Australia and the United Kingdom.


William L. Scarlett, D.O., FACS, FACOS, FAACS Associate Clinical Professor of Plastic Surgery PCOM, Philadelphia PA Director of Bucks County Aesthetic Center Bensalem, PA

Summary of a presentation made by Dr Scarlett

PROTOCOL: Patients underwent laser treatments once a week for a period of six weeks. They received 10 minute treatment using the 904nm laser. This was a 2cm square grid pattern with one minute of treatment in each area. (300 mJ/ 1 min treatment = 4.5 Joules/cm2.


  • 23 patients, 8 of which had previous radiation
  • Surgical intervention was avoided in 91.3% of patients with grade III/IV capsular contraction
  • Of the patients who avoided surgery, the laser improved the stiffness of the breast by 10.95% with an average of 50.2%
  • The overall improvement in comfort for these patients ranged from 10.95% with an average of 52.1%


  • LLLT is a promising alternative treatment for grades III & IV capsular contracture
  • In the majority of cases, both patients and surgeon observed significant tissue softening and improved breast contour after treatment with the LTU.904 laser
  • Factors to incorporate in subsequent studies to confirm validity of this pilot study: evaluation of current treatment protocol, randomized blinded study, larger patient population, objective measurement of the breast tissue changes and comparison to other non-invasive treatment methods.



Emily O'Brien1, Egon Perilli1, Eva Bezak2, Alan Wilson1, Colin Carati1
1Flinders University, South Australia, Australia
2Royal Adelaide Hospital, South Australia, Australia


BACKGROUND: Cosmetic reconstruction of the breast can involve implantation of a prosthetic device. These implants undergo deformation in 10-50% of cases, due to contraction of a fibrotic capsule that develops around them, resulting in their removal if the contracture is bad (Grade III or IV). Recent work in the US has shown that capsular contracture in humans can be improved by LLLT, based on its efficacy in treating lymphoedema and fibrosis. We evaluated the effect of LLLT on fibrosis associated with implant capsules in an animal model.

METHODS: Two silicone implants (provided by Mentor) were placed subcutaneously on the dorsum of mice and the implant site was irradiated (X-Rays, 10 gray) to induce fibrosis. The animals then received either LLLT or placebo 3 times per week for 3 weeks (n=5 in each group). Implants were imaged by microCT, and histological assessment of implant capsules was performed.

RESULTS: There was no evidence of capsular contracture in either group. Capsules surrounding implants receiving LLLT were better organised histologically, with tight connective tissue layers parallel to the capsule surface, well aligned fibroblasts and moderate inflammatory cell infiltrate. Capsules receiving placebo treatment were less well organised, with more random connective tissue and fibroblast cell orientation, a greater degree of interstitial space and more inflammatory cell infiltrate.

CONCLUSION: Capsular contracture was not induced in this model. LLLT resulted in a more organised capsular structure, and less inflammatory reaction to the implant. These observations may be relevant to the efficacy of LLLT in lymphoedema.

<Presented to the Australasian Lymphoedema Association, Auckland 3-5th April 2014>

For full research details on both studies, contact RianCorp


Copyright © 2015, All rights reserved.
You're receiving this email because you are a valued customer of RianCorp, or you have opted in to our mailing list.

Our mailing address is: PO Box 177, Marleston, SA 5033 Australia